|
1. Williams I. Epidemiology of
hepatitis C in the United States. Am J Med 1999;107:2S-9S.
2. Davis DL, Albright JE, Cook S, Rosenberg D. Projecting the
future healthcare burden from hepatitis C in the United States [abstract].
Hepatology 1998;28:309A. Abstract 909.
3. United Network for Organ Sharing Annual Report. www.unos.org 1999.
4. Feinstone SM. Hepatitis A: epidemiology and prevention. Eur J
Gastroenterol Hepatol 1996;8:300-305.
5. Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and
prevention. Clin Chem 1997;43:1494-1499.
6. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the
United States. Gastroenterol Clin North Am 1994;23:437-455.
7. Marcus EL, Tur-Kaspa R. Viral hepatitis in older adults. J Am
Geriatr Soc 1997;45:755-763.
8. Koff RS. Preventing hepatitis A infections in travelers to
endemic areas. Am J Trop Med Hyg 1995;53:586-590.
9. Langer BC, Frosner GG . Relative importance of the enterically
transmitted human hepatitis viruses type A and E as a cause of foreign
travel associated hepatitis. Arch Virol Suppl 1996;11:171-179.
10. Versalovic J. Hepatitis G virus clinical microbiol newsletter.
1997;19:161.
11. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. Fauci AS,
Braunwald E, Isselbacher KJ, et al. Harrison's Principles of Internal
Medicine. New York: McGraw-Hill, 1998:1677-1692.
12. Hochman JA, Balistreri WF. Viral hepatitis: expanding the
alphabet. Adv Pediatr 1999;46:207-243.
13. Koff RS. Clinical manifestations and diagnosis of hepatitis A
virus infection. Vaccine 1992;10(suppl 1):S15-S17.
14. Winn WC Jr. Enterically transmitted hepatitis. Hepatitis A and
E viruses. Clin Lab Med 1999;19:661-673.
15. Dusheiko GM. Review article: the management of hepatitis A, B,
D and non-A non-B. Aliment Pharmacol Ther 1989;3:1-20.
16. From the Centers for Disease Control and Prevention. Update:
recommendations to prevent hepatitis B virus transmission--United States.
JAMA 1999;281:790.
17. Kane MA, Alter MJ, Hadler SC, Margolis HS. Hepatitis B
infection in the United States. Recent trends and future strategies for
control. Am J Med 1989;87:11S-13S.
18. Malik AH, Lee WM. Chronic hepatitis B virus infection:
treatment strategies for the next millennium. Ann Intern Med 2000;132:723-731.
19. Alter MJ, Hadler SC, Margolis HS, et al. The changing
epidemiology of hepatitis B in the United States. Need for alternative
vaccination strategies. JAMA 1990;263:1218-1222.
20. Kaur S, Rybicki L, Bacon BR, et al. Performance
characteristics and results of a large-scale screening program for viral
hepatitis and risk factors associated with exposure to viral hepatitis B and
C: results of the National Hepatitis Screening Survey. National Hepatitis
Surveillance Group. Hepatology 1996;24:979-986.
21. Dickson RC, Everhart JE, Lake JR, et al. Transmission of
hepatitis B by transplantation of livers from donors positive for antibody
to hepatitis B core antigen. The National Institute of Diabetes and
Digestive and Kidney Diseases Liver Transplantation Database.
Gastroenterology 1997;113:1668-1674.
22. Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission
associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med
1983;99:330-333.
23. Apichartpiyakul C, Apichartpiyakul N, Urwijitaroon Y, et al.
Seroprevalence and subtype distribution of hepatitis C virus among blood
donors and intravenous drug users in northern/northeastern Thailand. Jpn J
Infect Dis 1999;52:121-123.
24. Berry WR, Gottesfeld RL, Alter HJ, Vierling JM. Transmission
of hepatitis B virus by artificial insemination. JAMA 1987;257:1079-1081.
25. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission
of hepatitis B, hepatitis C and human immunodeficiency viruses through
unsafe injections in the developing world: model-based regional estimates.
Bull World Health Organ 1999;77:801-807.
26. Dupuy JM, Giraud P, Dupuy C, Drouet J, Hoofnagle J. Hepatitis
B in children. II. Study of children born to chronic HBsAg carrier mothers.
J Pediatr 1978;92:200-204.
27. Papaevangelou G, Hoofnagle J, Kremastinou J. Transplacental
transmission of hepatitis-B virus by symptom-free chronic carrier mothers.
Lancet 1974;2:746-748.
28. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to
hepatitis C virus in multiply transfused patients with thalassaemia major. J
Clin Pathol 1990;43:638-640.
29. Holland PV, Alter HJ . The clinical significance of hepatitis
B virus antigens and antibodies. Med Clin North Am 1975;59:849-855.
30. Barker LF, Almeida JD, Hoofnagle JH, et al. Hepatitis B core
antigen: immunology and electron microscopy. J Virol 1974;14:1552-1558.
31. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that
anti-HBc but not HBV DNA testing may prevent some HBV transmission by
transfusion. Br J Haematol 1999;107:186-195.
32. Davis GL. Hepatitis B: diagnosis and treatment. South Med J
1997;90:866-870.
33. Imperial JC. Natural history of chronic hepatitis B and C. J
Gastroenterol Hepatol 1999;14(suppl):S1-S5.
34. Rogers M, Davis GL. Serology of acute and chronic type B
hepatitis. Dig Dis 1989; 7:255-264.
35. Yoo JY, Kim HY, Park CK, et al. Significance of hepatitis B
core antigen in the liver in patients with chronic hepatitis B and its
relation to hepatitis B virus DNA. J Gastroenterol Hepatol 1990;5:239-243.
36. Ballard AL, Boxall EH. Assessing the infectivity of hepatitis
B carriers. Commun Dis Public Health 1999;2:178-83.
37. Koff RS. Management of the hepatitis B surface antigen (HBsAg)
carrier. Semin Liver Dis 1981;1:33-43.
38. Tandon BN. Hepatitis B carrier: the correct nomenclature. Natl
Med J India 1999;12:141.
39. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis
and the "healthy" HBsAg carrier state. Hepatology 1987;7:758-763.
40. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course
of chronic hepatitis B. Hepatology 1999;30:257-264.
41. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of
hepatitis C virus infection in the United States, 1988 through 1994. N Engl
J Med 1999;341:556-562.
42. National Institutes of Health. National Institutes of Health
Consensus Development Conference Panel statement: Management of hepatitis C.
Hepatology 1997;26(suppl 1):2S-10S.
43. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis
C: update since the 1997 National Institutes of Health Consensus Development
Conference. J Gastroenterol Hepatol 1999;14(suppl):S12--S18.
44. Alter H. Discovery of non-A, non-B hepatitis and
identification of its etiology. Am J Med 1999;107:16S-20S.
45. Alter HJ. To C or not to C: these are the questions. Blood
1995;85:1681-1695.
46. Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C
in asymptomatic blood donors. Hepatology 1997;26:29S-33S.
47. Lam NP. Hepatitis C: natural history, diagnosis, and
management. Am J Health Syst Pharm 1999;56:961-973.
48. Sarbah SA, Younossi ZM. Hepatitis C, an update on the silent
epidemic. J Clin Gastroenterol 2000;30:125-143.
49. Brechot C. Hepatitis C virus: molecular biology and genetic
variability. Dig Dis Sci 1996;41:6S-21S.
50. Esteban JI, Genesca J, Alter HJ. Hepatitis C: molecular
biology, pathogenesis, epidemiology, clinical features, and prevention. Prog
Liver Dis 1992;10:253-282.
51. Strader DB, Seeff LB . The natural history of chronic
hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-328.
52. Fang JWS, Chow V, Lau JYN. Virology of the hepatitis C virus.
Clinics in Liver Disease 1997;1:493-514.
53. Dentico P, Curatolo N, Sacco R, et al. Hepatitis C virus
serotypes and sources of infection in patients with HCV-related chronic
liver disease from one geographical area in southeast Italy. Infection 1999;27:118-121.
54. Orito E, Mizokami M, Mizoguchi N, et al. Hepatitis C virus
serotype II responds more favorably to interferon-alpha therapy. J Hepatol
1994;21:130-132.
55. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al.
Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis
C virus serotypes. Ann Intern Med 1995;122:169-173.
56. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the
efficacy of interferon therapy in chronic hepatitis C virus infection.
Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558-566.
57. Davis GL. Hepatitis C virus genotypes and quasispecies. Am J
Med 1999;107:21S-26S.
58. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C
virus genotypes: an investigation of type-specific differences in geographic
origin and disease. Hepatology 1994;19:13-18.
59. Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus
infection in kidney transplant recipients [published erratum appears in
Hepatology 1994 May;19(5):1329]. Hepatology 1993;18:1027-1031.
60. Afonso AM, Jiang J, Penin F, et al. Nonrandom distribution of
hepatitis C virus quasispecies in plasma and peripheral blood mononuclear
cell subsets. J Virol 1999;73:9213-9221.
61. Farci P, Bukh J, Purcell RH. The quasispecies of hepatitis C
virus and the host immune response. Springer Semin Immunopathol 1997;19:5-26.
62. Farci P, Shimoda A, Coiana A, et al. The outcome of acute
hepatitis C predicted by the evolution of the viral quasispecies. Science
2000;288:339-344.
63. Gretch DR, Polyak SJ, Wilson JJ, et al. Tracking hepatitis C
virus quasispecies major and minor variants in symptomatic and asymptomatic
liver transplant recipients. J Virol 1996;70:7622-7631.
64. Pawlotsky JM, Germanidis G, Neumann AU, et al. Interferon
resistance of hepatitis C virus genotype 1b: relationship to nonstructural
5A gene quasispecies mutations. J Virol 1998;72:2795-2805.
65. Bell H, Hellum K, Harthug S, et al. Genotype, viral load and
age as independent predictors of treatment outcome of interferon-alpha 2a
treatment in patients with chronic hepatitis C. Construct group. Scand J
Infect Dis 1997;29:17-22.
66. Booth JC, Foster GR, Kumar U, et al. Chronic hepatitis C virus
infections: predictive value of genotype and level of viraemia on disease
progression and response to interferon alpha. Gut 1995;36:427-432.
67. Chayama K, Tsubota A, Arase Y, et al. Genotype, slow decrease
in virus titer during interferon treatment and high degree of sequence
variability of hypervariable region are indicative of poor response to
interferon treatment in patients with chronic hepatitis type C. J Hepatol
1995;23:648-653.
68. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence
and pathogenesis of hepatitis C virus. Trends Microbiol 1999;7:402-410.
69. Polyak SJ, Faulkner G, Carithers RL Jr, Corey L, Gretch DR.
Assessment of hepatitis C virus quasispecies heterogeneity by gel shift
analysis: correlation with response to interferon therapy. J Infect Dis
1997;175:1101-1107.
70. Dienstag JL, Alter HJ. Non-A, non-B hepatitis: evolving
epidemiologic and clinical perspective. Semin Liver Dis 1986;6:67-81.
71. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B
post-transfusion hepatitis. Looking back in the second decade [see
comments]. Ann Intern Med 1993;119:110-115.
72. Purcell R. The hepatitis C virus: overview. Hepatology 1997;26(suppl
1):11S-14S.
73. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of
transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor
Study. N Engl J Med 1996;334:1685-1690.
74. Alter HJ, Chalmers TC, Freeman BM, et al. Health-care workers
positive for hepatitis B surface antigen. Are their contacts at risk? N Engl
J Med 1975;292:454-457.
75. Hamid SS, Farooqui B, Rizvi Q, Sultana T, Siddiqui AA. Risk of
transmission and features of hepatitis C after needlestick injuries. Infect
Control Hosp Epidemiol 1999;20:63-64.
76. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus
infection. Sex Transm Infect 1998;74:399-404.
77. Dienstag JL. Sexual and perinatal transmission of hepatitis C.
Hepatology 1997;26:66S-70S.
78. Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus
infection among sexually promiscuous groups and the heterosexual partners of
hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis
1993;12:827-831.
79. Wejstal R. Sexual transmission of hepatitis C virus. J Hepatol
1999;31(suppl 1):92-95.
80. National guideline for the management of the viral hepatitides A, B,
and C. Clinical Effectiveness Group (Association of Genitourinary Medicine
and the Medical Society for the Study of Venereal Diseases). Sex Transm
Infect 1999;75(suppl 1):S57-S64.
81. Resti M. Mother-to-infant transmission of hepatitis C virus.
Ital J Gastroenterol Hepatol 1999;31:489-493.
82. Alberti A, Chemello L, Benvegnu L. Natural history of
hepatitis C. J Hepatol 1999;31(suppl 1):17-24.
83. Alter MJ, Margolis HS, Krawczynski K, et al. The natural
history of community-acquired hepatitis C in the United States. The Sentinel
Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-1905.
84. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course
and risk factors of hepatitis C virus related liver disease in the general
population: report from the Dionysos study. Gut 1999;44:874-880.
85. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence
and clinical course of chronic hepatitis C virus (HCV) infection and rate of
HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology
2000;31:751-755.
86. Colombo M. Natural history and pathogenesis of hepatitis C
virus related hepatocellular carcinoma. J Hepatol 1999;31(suppl 1):25-30.
87. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes
after transfusion-associated hepatitis C [see comments]. N Engl J Med 1995;332:1463-6.
88. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med
1996;125:658-668.
89. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of
hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111.
90. Albloushi SS, Murray FE, Callagy G, et al. Changes in liver
histopathology in women infected with hepatitis C through contaminated
anti-D immunoglobulin injections in Ireland. Eur J Gastroenterol Hepatol
1998;10:69-73.
91. Coelho-Little ME, Jeffers LJ, Bernstein DE, et al. Hepatitis C
virus in alcoholic patients with and without clinically apparent liver
disease. Alcohol Clin Exp Res 1995;19:1173-1176.
92. Degos F. Hepatitis C and alcohol. J Hepatol 1999;31(suppl
1):113-118.
93. Chang MH, Chen DS. Prospects for hepatitis B virus eradication
and control of hepatocellular carcinoma. Baillieres Best Pract Res Clin
Gastroenterol 1999;13:511-517.
94. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence
of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Cancer 1999;85:2132-2137.
95. Colombo M. Hepatitis C virus and hepatocellular carcinoma.
Baillieres Best Pract Res Clin Gastroenterol 1999;13:519-528.
96. Dusheiko GM. Hepatocellular carcinoma associated with chronic
viral hepatitis. Aetiology, diagnosis and treatment. Br Med Bull 1990;46:492-511.
97. Simonetti RG, Camma C, Fiorello F, et al. Hepatocellular
carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-972.
98. Korenman J, Baker B, Waggoner J, et al. Long-term remission of
chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634.
99. Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical,
biochemical and histological features in 102 patients with chronic hepatitis
C virus infection. Q J Med 1993;86:119-125.
100. Hadziyannis SJ. Review: hepatitis delta. J Gastroenterol
Hepatol 1997;12:289-298.
101. Hoofnagle JH. Type D (delta) hepatitis. JAMA 1989;261:1321-1325.
102. Jacobson IM, Dienstag JL, Werner BG, et al. Epidemiology and
clinical impact of hepatitis D virus (delta) infection. Hepatology 1985;5:188-191.
103. Liaw YF, Tsai SL, Sheen IS, et al. Clinical and virological
course of chronic hepatitis B virus infection with hepatitis C and D virus
markers. Am J Gastroenterol 1998;93:354-359.
104. Polish LB, Gallagher M, Fields HA, Hadler SC. Delta
hepatitis: molecular biology and clinical and epidemiological features. Clin
Microbiol Rev 1993;6:211-229.
105. Dusheiko GM, Brink BA, Conradie JD, Marimuthu T, Sher R.
Regional prevalence of hepatitis B, delta, and human immunodeficiency virus
infection in southern Africa: a large population survey. Am J Epidemiol
1989;129:138-145.
106. Irshad M, Acharya SK. Hepatitis D virus (HDV) infection in
severe forms of liver diseases in north India. Eur J Gastroenterol Hepatol
1996;8:995-998.
107. Kullavanijaya P, Tangkijvanich P, Poovorawan Y. Current
status of infection-related gastrointestinal and hepatobiliary diseases in
Thailand. Southeast Asian J Trop Med Public Health 1999;30:96-105.
108. Navascues CA, Rodriguez M, Sotorrio NG, et al. Epidemiology
of hepatitis D virus infection: changes in the last 14 years. Am J
Gastroenterol 1995;90:1981-1984.
109. Bhattacharyya S, Dalal BS, Lahiri A. Hepatitis D infectivity
profile among hepatitis B infected hospitalised patients in Calcutta. Indian
J Public Health 1998;42:108-112.
110. Cotrina M, Buti M, Jardi R, et al. Hepatitis delta genotypes
in chronic delta infection in the northeast of Spain (Catalonia). J Hepatol
1998;28:971-977.
111. Weisfuse IB, Hadler SC, Fields HA, et al. Delta hepatitis in
homosexual men in the United States. Hepatology 1989;9:872-874.
112. Ponzetto A, Seeff LB, Buskell-Bales Z, et al. Hepatitis B
markers in United States drug addicts with special emphasis on the delta
hepatitis virus. Hepatology 1984;4:1111-1115.
113. Ponzetto A, Hoofnagle JH, Seeff LB. Antibody to the hepatitis
B virus-associated delta-agent in immune serum globulins. Gastroenterology
1984;87:1213-1216.
114. Taylor JM. Human hepatitis delta virus: an agent with
similarities to certain satellite RNAs of plants. Curr Top Microbiol Immunol
1999;239:107-122.
115. Taylor JM. Replication of human hepatitis delta virus:
influence of studies on subviral plant pathogens. Adv Virus Res 1999;54:45-60.
116. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM.
Elimination of hepatitis delta virus infection after loss of hepatitis B
surface antigen in patients with chronic delta hepatitis. J Med Virol 1994;44:389-392.
117. Craxi A, Tine F, Vinci M, et al. Transmission of hepatitis B
and hepatitis delta viruses in the households of chronic hepatitis B surface
antigen carriers: a regression analysis of indicators of risk. Am J
Epidemiol 1991;134:641-650.
118. ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248,
July 1998 (replaces No. 174, November 1992). American College of
Obstetricians and Gynecologists. Int J Gynaecol Obstet 1998;63:195-202.
119. Dinsmoor MJ. Hepatitis in the obstetric patient. Infect Dis
Clin North Am 1997;11:77-91.
120. Buti M, Esteban R, Jardi R, et al. Clinical and serological
outcome of acute delta infection. J Hepatol 1987;5:59-64.
121. Koff RS. Fulminant hepatitis due to HBV/HDV coinfection. Hosp
Pract (Off Ed) 1987;22:123-130, 139-140, 145-150 passim.
122. Mas A, Buti M, Esteban R, et al. Hepatitis B virus and
hepatitis D virus replication in HBsAg-positive fulminant hepatitis.
Hepatology 1990;11 :1062-1065.
123. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection
with hepatitis B and C or B, C and delta viruses results in severe chronic
liver disease and responds poorly to interferon-alpha treatment. J Viral
Hepat 1995;2:39-45.
124. Fattovich G, Giustina G, Christensen E, et al. Influence of
hepatitis delta virus infection on morbidity and mortality in compensated
cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).
Gut 2000;46 :420-426.
125. Buti M, Esteban R, Roggendorf M, et al. Hepatitis D virus RNA
in acute delta infection: serological profile and correlation with other
markers of hepatitis D virus infection. Hepatology 1988;8:1125-1129.
126. Buti M, Amengual MJ, Esteban R, et al. Serological profile of
tissue autoantibodies during acute and chronic delta hepatitis. J Hepatol
1989;9:345-350.
127. Chu CM, Yeh CT, Liaw YF. Viral superinfection in previously
unrecognized chronic carriers of hepatitis B virus with superimposed acute
fulminant versus nonfulminant hepatitis. J Clin Microbiol 1999;37:235-237.
128. Huo TI, Wu JC, Lai CR, et al. Comparison of clinico-pathological
features in hepatitis B virus-associated hepatocellular carcinoma with or
without hepatitis D virus superinfection. J Hepatol 1996;25:439-444.
129. Mendez L, Reddy KR, Di Prima RA, Jeffers LJ, Schiff ER.
Fulminant hepatic failure due to acute hepatitis B and delta co-infection:
probable bloodborne transmission associated with a spring-loaded fingerstick
device. Am J Gastroenterol 1991; 86:895-897.
130. Agarwal SK, Irshad M, Dash SC. Prevalence of antibodies
against hepatitis E virus in haemodialysis patients in India. Nephron 1999;81:448.
131. Aggarwal R, Naik SR . Epidemiology of hepatitis E: past,
present and future. Trop Gastroenterol 1997;18:49-56.
132. Aggarwal R, Krawczynski K. Hepatitis E: an overview and
recent advances in clinical and laboratory research. J Gastroenterol Hepatol
2000;15:9-20.
133. al-Azmeh J, Frosner G, Darwish Z, Bashour H, Monem F.
Hepatitis E in Damascus, Syria. Infection 1999;27:221-223.
134. Arankalle VA, Chadha MS, Mehendale SM, Tungatkar SP. Epidemic
hepatitis E: serological evidence for lack of intrafamilial spread. Indian J
Gastroenterol 2000;19:24-28.
135. Chandler JD, Riddell MA, Li F, Love RJ, Anderson DA.
Serological evidence for swine hepatitis E virus infection in Australian pig
herds. Vet Microbiol 1999;68:95-105.
136. Harrison TJ. Hepatitis E virus -- an update. Liver 1999;19:171-176.
137. Hsieh SY, Meng XJ, Wu YH, et al. Identity of a novel swine
hepatitis E virus in Taiwan forming a monophyletic group with Taiwan
isolates of human hepatitis E virus. J Clin Microbiol 1999;37:3828-3834.
138. Labrique AB, Thomas DL, Stoszek SK, Nelson KE. Hepatitis E:
an emerging infectious disease. Epidemiol Rev 1999;21:162-179.
139. Meng XJ, Dea S, Engle RE, et al. Prevalence of antibodies to
the hepatitis E virus in pigs from countries where hepatitis E is common or
is rare in the human population. J Med Virol 1999;59:297-302.
140. Wu JC, Chen CM, Chiang TY, et al. Clinical and
epidemiological implications of swine hepatitis E virus infection. J Med
Virol 2000;60:166-171.
141. Karetnyi YV, Gilchrist MJ, Naides SJ. Hepatitis E virus
infection prevalence among selected populations in Iowa. J Clin Virol 1999;14:51-55.
142. Mast EE, Kuramoto IK, Favorov MO, et al. Prevalence of and
risk factors for antibody to hepatitis E virus seroreactivity among blood
donors in Northern California. J Infect Dis 1997;176:34-40.
143. Ooi WW, Gawoski JM, Yarbough PO, Pankey GA. Hepatitis E
seroconversion in United States travelers abroad. Am J Trop Med Hyg 1999;61:822-824.
144. Zaaijer HL, Mauser-Bunschoten EP, ten Veen JH, et al.
Hepatitis E virus antibodies among patients with hemophilia, blood donors,
and hepatitis patients. J Med Virol 1995;46:244-246.
145. Irshad M. Hepatitis E virus: an update on its molecular,
clinical and epidemiological characteristics. Intervirology 1999;42:252-262.
146. Corwin AL, Tien NT, Bounlu K, et al. The unique riverine
ecology of hepatitis E virus transmission in South-East Asia. Trans R Soc
Trop Med Hyg 1999;93:255-260.
147. Buti M, Jardi R, Cotrina M, et al. Hepatitis E virus
infection in acute hepatitis in Spain. J Virol Methods 1995;55:49-54.
148. Mast EE, Purdy MA, Krawczynski K. Hepatitis E. Baillieres
Clin Gastroenterol 1996;10:227-242.
149. Mast EE, Krawczynski K. Hepatitis E: an overview. Annu Rev
Med 1996;47:257-266.
150. Mateos ML, Camarero C, Lasa E, et al. Hepatitis E virus:
relevance in blood donors and other risk groups. Vox Sang 1998;75:267-269.
151. Michielsen PP, Van Damme P. Viral hepatitis and pregnancy.
Acta Gastroenterol Belg 1999;62:21-29.
152. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E
hepatitis in the United States and the role of hepatitis G virus infection.
Sentinel Counties Viral Hepatitis Study Team. N Engl J Med 1997;336:741-746.
153. Liaw YF. Current therapeutic trends in therapy for chronic
viral hepatitis. J Gastroenterol Hepatol 1997;12(suppl):S346-S353.
154. Cheung RC, Keeffe EB, Greenberg HB. Hepatitis G virus: is it
a hepatitis virus? West J Med 1997;167:23-33.
155. Heinsen A, Fomsgaard A. [Hepatitis G virus or hepatitis GB
virus C]. Ugeskr Laeger 1999;161:2653-2656.
156. Bricaire F. [Hepatitis G virus: a new agent responsible for
viral hepatitis]. Bull Soc Pathol Exot 1998;91:34-36.
157. Prevention of hepatitis A infections: guidelines for use of
hepatitis A vaccine and immune globulin. American Academy of Pediatrics
Committee on Infectious Diseases. Pediatrics 1996;98:1207-1215.
158. Prevention of hepatitis A through active or passive immunization:
Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep 1996;45:1-30.
159. Prevention of hepatitis A through active or passive immunization:
Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep 1999;48:1-37.
160. Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A.
Simultaneous passive and active immunization against hepatitis A. Vaccine
1992;10(suppl 1):S138-S141.
161. Hollinger FB, Eickhoff T, Gershon A, Jong EC, Koff RS.
Discussion: who should receive hepatitis A vaccine? A strategy for
controlling hepatitis A in the United States. J Infect Dis 1995;171(suppl
1):S73-S77.
162. Dolan SA. Vaccines for hepatitis A and B. The latest
recommendations on safe and extended protection. Postgrad Med 1997;102:74-80.
163. Duff B, Duff P. Hepatitis A vaccine: ready for prime time.
Obstet Gynecol 1998;91:468-471.
164. Horng YC, Chang MH, Lee CY, et al. Safety and immunogenicity
of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993;12:359-362.
165. Block SL, Hedrick JA, Tyler RD, et al. Safety, tolerability
and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in
rural Kentucky children. Pediatr Infect Dis J 1993;12:976-980.
166. Grob P, Hallauer J, Kane M, et al. Hepatitis B: a serious
public health threat. Viral Hepatitis Prevention Board. Vaccine 1998;16(suppl):S1-S2.
167. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment.
Clin Chem 1997;43:1500-1506.
168. Hepatitis B virus: a comprehensive strategy for eliminating
transmission in the United States through universal childhood vaccination.
Recommendations of the Immunization Practices Advisory Committee (ACIP).
MMWR Morb Mortal Wkly Rep 1991;40:1-25.
169. Update: recommendations to prevent hepatitis B virus
transmission--United States. MMWR Morb Mortal Wkly Rep 1999;48:33-34.
170. Miller ER, Alter MJ, Tokars JI. Protective effect of
hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999;33:356-360.
171. Koff RS, Slavin MM, Connelly JD, Rosen DR. Contagiousness of
acute hepatitis B. Secondary attack rates in household contacts.
Gastroenterology 1977;72:297-300.
172. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of
hepatitis B virus transmission by immunization. An economic analysis of
current recommendations. JAMA 1995;274:1201-1208.
173. Mulley AG, Silverstein MD, Dienstag JL. Indications for use
of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med
1982;307 :644-652.
174. Buti M, Viladomiu L, Jardi R, et al. Long-term immunogenicity
and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol
1992;12:144-147.
175. De Gast GC, Houwen B, van der Hem GK, The TH. T-lymphocyte number
and function and the course of hepatitis B in hemodialysis patients.
Infect. 1976;14:1138-43.
176. Douvin C, Simon D, Charles MA, et al. Hepatitis B vaccination
in diabetic patients. Randomized trial comparing recombinant vaccines
containing and not containing pre-S2 antigen. Diabetes Care 1997;20:148-151.
177. Mitwalli A. Responsiveness to hepatitis B vaccine in
immunocompromised patients by doubling the dose scheduling. Nephron 1996;73:417-420.
178. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high
and accelerated dose of hepatitis B vaccine in alcoholic patients: a
randomized clinical trial. Am J Med 1997;103:217-222.
179. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine
in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J
Med 1984;311:496-501.
180. Goldwater PN. Randomized, comparative trial of 20 micrograms
vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders.
Vaccine 1997;15:353-356.
181. Zannolli R, Morgese G. Hepatitis B vaccine: current issues.
Ann Pharmacother 1997;31:1059-1067.
182. Marchou B, Picot N, Chavanet P, et al. Three-week hepatitis B
vaccination provides protective immunity. Vaccine 1993;11:1383-1385.
183. Marchou B, Excler JL, Bourderioux C, et al. A 3-week
hepatitis B vaccination schedule provides rapid and persistent protective
immunity: a multicenter, randomized trial comparing accelerated and classic
vaccination schedules. J Infect Dis 1995;172:258-260.
184. Bryan JP, Sjogren M, Iqbal M, et al. Comparative trial of
low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines.
J Infect Dis 1990;162:789-793.
185. Szmuness W, Stevens CE, Harley EJ, et al. The immune response
of healthy adults to a reduced dose of hepatitis B vaccine. J Med Virol
1981;8:123-129.
186. NIH Consensus Statement. Management of Hepatitis C. NIH
Consens Statement 1997; 15:1-41.
187. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of
immune globulin on the prevention of experimental hepatitis C virus
infection. J Infect Dis 1996;173:822-828.
188. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission
of the hepatitis C virus and efficacy of prophylaxis with intramuscular
immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-1544.
189. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome
of orthotopic liver transplantation for chronic hepatitis B cirrhosis with
aggressive passive immunization. Transplantation 1996;61:1358-1364.
190. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical
outcomes with liver transplantation for hepatitis B-induced chronic liver
failure using passive immunization. Ann Surg 1998;227:841-850.
191. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of
hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94:1601-1604.
192. Kurstak E, Hossain A, Kurstak C. Progress in diagnosis of
viral hepatitis A, B, C, D and E. Acta Virol 1996;40:107-115.
193. Saab S, Martin P. Tests for acute and chronic viral
hepatitis. Finding your way through the alphabet soup of infection and
superinfection. Postgrad Med 2000;107:123-126,129-130.
194. McPherson RA. Laboratory diagnosis of human hepatitis
viruses. J Clin Lab Anal 1994;8:369-377.
195. Waite J. The laboratory diagnosis of the hepatitis viruses.
Int J STD AIDS 1996; 7:400-407.
196. Yang G, Vyas GN. Immunodiagnosis of viral hepatitides A to E
and non-A to -E. Clin Diagn Lab Immunol 1996;3:247-256.
197. Bradley DW, Maynard JE, Hindman SH, et al. Serodiagnosis of
viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis
A virus by radioimmunoassay. J Clin Microbiol 1977;5:521-530.
198. Flehmig B, Ranke M, Berthold H, Gerth HJ. A solid-phase
radioimmunoassay for detection of IgM antibodies to hepatitis A virus. J
Infect Dis 1979;140:169-175.
199. Pawlotsky JM, Bastie A, Lonjon I, et al. What technique
should be used for routine detection and quantification of HBV DNA in
clinical samples? J Virol Methods 1997;65:245-253.
200. Pawlotsky JM, Bastie A, Hezode C, et al. Routine detection
and quantification of hepatitis B virus DNA in clinical laboratories:
performance of three commercial assays. J Virol Methods 2000;85:11-21.
201. Kuttner G, Kramer A, Schmidtke G, et al. Characterization of
neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and
their fragments. Mol Immunol 1999;36:669-683.
202. Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN.
Comparison of methods for detection of hepatitis B virus DNA. J Clin
Microbiol 1994;32 :2088-2091.
203. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D.
Epidemiological factors affecting the severity of hepatitis C virus- related
liver disease: a French survey of 6,664 patients. The Study Group for the
Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-490.
204. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone
derived from a blood-borne non-A, non-B viral hepatitis genome. Science
1989;244:359-362.
205. Crutcher M, Holt K. From the Oklahoma State Department of
Health. CDC recommendations for diagnosis and initial management of
hepatitis C virus infection. J Okla State Med Assoc 1999;92:93-95.
206. Moyer LA, Mast EE, Alter MJ. Hepatitis C: Part I. Routine
serologic testing and diagnosis. Am Fam Physician 1999;59:79-88,91-92.
207. Muller C. The hepatitis alphabet--hepatitis A-G and TTV. Wien
Klin Wochenschr 1999;111:461-468.
208. Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol
1999;31(suppl 1):71-79.
209. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody
to hepatitis C virus in prospectively followed transfusion recipients with
acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
210. Alter HJ. New kit on the block: evaluation of
second-generation assays for detection of antibody to the hepatitis C virus
[editorial; comment]. Hepatology 1992; 15:350-353.
211. Allander T, Beyene A, Jacobson SH, Grillner L, Persson MA.
Patients infected with the same hepatitis C virus strain display different
kinetics of the isolate-specific antibody response. J Infect Dis 1997;175:26-31.
212. Clemens JM, Taskar S, Chau K, et al. IgM antibody response in
acute hepatitis C viral infection. Blood 1992;79:169-172.
213. Spengler U, Lechmann M, Irrgang B, Dumoulin FL, Sauerbruch T.
Immune responses in hepatitis C virus infection. J Hepatol 1996;24:20-25.
214. Cordoba J, Olaso V, Molina JM, et al. [Comparative analysis
of viral load by bDNA HCV RNA-2.0 and amplicor HCV monitor in patients with
hepatitis C infection]. Enferm Infecc Microbiol Clin 2000;18:6-11.
215. Martinot-Peignoux M, Boyer N, Le Breton V, et al. A new step
toward standardization of serum hepatitis C virus-RNA quantification in
patients with chronic hepatitis C. Hepatology 2000;31:726-729.
216. Pockros PJ, Bain VG, Hunter EB, et al. A comparison of
reverse transcription-polymerase chain reaction and branched-chain DNA
assays for hepatitis C virus RNA in patients receiving interferon treatment.
J Viral Hepat 1999;6 :145-150.
217. Yu ML, Chuang WL, Chen SC, et al. Clinical application of the
Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum
hepatitis C virus RNA. J Clin Pathol 1999;52:807-811.
218. Robbins DJ, Pasupuleti V, Cuan J, Chiang CS. Reverse
transcriptase PCR quantitation of hepatitis C virus. Clin Lab Sci 2000;13:23-30.
219. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic
improvement and loss of detectable intrahepatic HCV RNA in patients with
chronic hepatitis C and sustained response to interferon-alpha therapy. Ann
Intern Med 1997;127:875-881.
220. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b
alone or in combination with ribavirin for the treatment of relapse of
chronic hepatitis C. International Hepatitis Interventional Therapy Group. N
Engl J Med 1998;339:1493-1499.
221. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon
alfa-2b alone or in combination with ribavirin as initial treatment for
chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med
1998;339:1485-1492.
222. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of
interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus
interferon alpha2b plus placebo for 48 weeks for treatment of chronic
infection with hepatitis C virus. International Hepatitis Interventional
Therapy Group (IHIT). Lancet 1998;352:1426-1432.
223. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al.
Hepatitis C virus genotypes in France: relationship with epidemiology,
pathogenicity and response to interferon therapy. J Viral Hepat 1999;6:435-443.
224. Clarysse C, Van den Eynde C, Nevens F, et al. Genotype, serum
level of HCV-RNA and response to interferon-alpha treatment in patients with
chronic hepatitis C. Neth J Med 1995;47:265-271.
225. Magrin S, Craxi A, Fabiano C, et al. HCV viraemia is more
important than genotype as a predictor of response to interferon in Sicily
(southern Italy). J Hepatol 1996;25:583-590.
226. Martinot-Peignoux M, Marcellin P, Pouteau M, et al.
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus
genotype are the main and independent prognostic factors of sustained
response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
227. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T.
Usefulness of simple assays for serum concentration of hepatitis C virus RNA
and HCV genotype in predicting the response of patients with chronic
hepatitis C to interferon alpha 2a therapy. J Med Virol 1995;46:162-168.
228. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C
virus genotype 4 is associated with a poor response to interferon-alpha
[letter]. Ann Intern Med 2000;132:845-846.
229. Modahl LE, Lai MM. Hepatitis delta virus: the molecular basis
of laboratory diagnosis. Crit Rev Clin Lab Sci 2000;37:45-92.
230. Lok AS, Soldevila-Pico C. Epidemiology and serologic
diagnosis of hepatitis E. J Hepatol 1994;20:567-569.
231. Mast EE, Alter MJ, Holland PV, Purcell RH. Evaluation of
assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus
Antibody Serum Panel Evaluation Group. Hepatology 1998;27:857-861.
232. Negro F, Rizzetto M . Diagnosis of hepatitis delta virus
infection. J Hepatol 1995;22:136-139.
233. Dienstag JL, Isselbacher KJ. Chronic Viral Hepatitis. In:
Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of
Internal Medicine. 14th ed. New York: McGaw-Hill, 1998:1696-1704.
234. Farrell GC. Acute viral hepatitis. Med J Aust 1998;168:565-570.
235. Chalmers TC. Rest and exercise in hepatitis. N Engl J Med
1969;281:1421-1422.
236. Hoofnagle JH. Therapy of acute and chronic viral hepatitis.
Adv Intern Med 1994; 39:241-275.
237. Noskin GA. Prevention, diagnosis, and management of viral
hepatitis. A guide for primary care physicians. AMA Advisory Group on
Prevention, Diagnosis, and Management of Viral Hepatitis. Arch Fam Med 1995;4:923-934.
238. Dienstag JL, Isselbacher KJ. Therapy for acute and chronic
hepatitis. Arch Intern Med 1981;141:1419-1423.
239. Silverberg M, Wherrett B, Worden E, Neumann PZ. An evaluation
of rest and low-fat diets in the management of acute infectious hepatitis. J
Pediatr 1969;74:260-264.
240. Gerety RJ, Hoofnagle JH, Markenson JA, Barker LF. Exposure to
hepatitis B virus and development of the chronic HBAg carrier state in
children. J Pediatr 1974;84:661-665.
241. Ruiz-Moreno M. Chronic hepatitis B in children. Natural
history and treatment. J Hepatol 1993;17(suppl 3):S64-S66.
242. Fong TL, Di Bisceglie AM, Biswas R, et al. High levels of
viral replication during acute hepatitis B infection predict progression to
chronicity. J Med Virol 1994;43:155-158.
243. Scheig R. Acute and chronic viral hepatitis. Lippincotts Prim
Care Pract 1998;2:390-397.
244. Bernal W, Wendon J. Acute liver failure; clinical features
and management. Eur J Gastroenterol Hepatol 1999;11:977-984.
245. Plevris JN, Schina M, Hayes PC. Review article: the
management of acute liver failure. Aliment Pharmacol Ther 1998;12:405-418.
246. Smithson JE, Neuberger JM. Acute liver failure. Overview. Eur
J Gastroenterol Hepatol 1999;11:943-947.
247. Williams R. Classification, etiology, and considerations of
outcome in acute liver failure. Semin Liver Dis 1996;16:343-348.
248. Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute
hepatitis C: increased risk in chronic carriers of hepatitis B virus [see
comments]. Gut 1999;45:613-617.
249. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N,
Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or
chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999;93:745-751.
250. Camma C, Giunta M, Chemello L, et al. Chronic hepatitis C:
interferon retreatment of relapsers. A meta-analysis of individual patient
data. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology
1999;30:801-807.
251. Camma C, Giunta M, Pinzello G, et al. Chronic hepatitis C and
interferon alpha: conventional and cumulative meta-analyses of randomized
controlled trials. Am J Gastroenterol 1999;94:581-595.
252. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic
hepatitis C with recombinant interferon alfa. A multicenter randomized,
controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
253. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic
hepatitis C with recombinant alpha-interferon. A multicentre randomized,
controlled trial. The Hepatitis Interventional Therapy Group. J Hepatol
1990;11 (Suppl 1):S31-S35.
254. Davis GL. Interferon therapy for chronic hepatitis C.
Baillieres Clin Gastroenterol 1996;10:289-98.
255. Davis GL, Lau JY. Factors predictive of a beneficial response
to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S-127S.
256. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of
interferon randomized trials in the treatment of viral hepatitis C: effects
of dose and duration. Hepatology 1996;24:778-89.
257. Younossi ZM. Chronic hepatitis C: a clinical overview. Clin J
Med 1997;64:259-268.
258. Bekkering FC, Brouwer JT, Leroux-Roels G, et al. Ultrarapid
hepatitis C virus clearance by daily high-dose interferon in non-responders
to standard therapy. J Hepatology 1998;28:960-964.
259. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B.
High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing
patients with chronic hepatitis C. A controlled randomized trial. Dig Dis
Sci 1996;41:149-154.
260. Di Marco V, Lo Iacono O, Camma C, et al. A randomized
controlled trial of high-dose maintenance interferon therapy in chronic
hepatitis C. J Med Virol 1997;51:17-24.
261. Shiffman ML. Use of high-dose interferon in the treatment of
chronic hepatitis C. Semin Liver Dis 1999;19 (suppl 1):25-33.
262. Chen C, Guo SM, Liu B. A randomized controlled trial of
kurorinone versus interferon-alpha2a treatment in patients with chronic
hepatitis B. J Viral Hepat 2000;3:225-229.
263. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon
for prevention of hepatocellular carcinoma in cirrhotic patients with
hepatitis B or hepatitis C virus infection. Ann Intern Med 1999;131:696-701.
264. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant
interferon-alpha 2a hastens the rate of HBeAg clearance in children with
chronic hepatitis B. Hepatology 1994;20:287-90.
265. Bruch HR, Korn A, Klein H, et al. Treatment of chronic
hepatitis B with interferon alpha-2b and interleukin-2. J Hepatol 1993;17(suppl
3):S52-S55.
266. Brunetto MR, Oliveri F, Demartini A, et al. Treatment with
interferon of chronic hepatitis B associated with antibody to hepatitis B e
antigen. J Hepatol 1991;13(suppl 1):S8-S11.
267. Di Bisceglie AM, Rustgi VK, Kassianides C, et al. Therapy of
chronic hepatitis B with recombinant human alpha and gamma interferon.
Hepatology 1990;11:266-270.
268. Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized,
controlled trial of recombinant alpha-interferon therapy for chronic
hepatitis B. Am J Gastroenterol 1993;88:1887-1892.
269. Hope RL, Weltman M, Dingley J, et al. Interferon alfa for
chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and
predictors of response. Med J Aust 1995;162:8-11.
270. Tong MJ, Blatt LM, Resser KJ, et al. Treatment of chronic
hepatitis C virus infection with recombinant consensus interferon. J
Interferon Cytokine Res 1998;18:81-6.
271. Brenard R. Practical management of patients treated with
alpha interferon. Acta Gastroenterol Belg 1997;60:211-3.
272. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin
therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin
Liver Dis 1999;19 (suppl 1):67-75.
273. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM.
Hepatitis C, Interferon Alfa, and Depression. Hepatology 2000;31:1207-1211.
274. McHutchison JG, Poynard T. Combination therapy with
interferon plus ribavirin for the initial treatment of chronic hepatitis C.
Semin Liver Dis 1999;19 (suppl 1):57-65.
275. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P.
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol
1998;25(suppl 1):39-47.
276. Valentine AD, Meyers CA. Successful treatment of
interferon-alpha-induced mood disorder with nortriptyline [letter; comment].
Psychosomatics 1995;36:418-419.
277. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible
mechanisms of action and reasons for failure of antiviral therapy in chronic
hepatitis C. J Hepatol 1999;31(Suppl 1):152-159.
278. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the
combination of interferon alfa and ribavirin as therapy of recurrent
hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
279. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is
an "a la carte" combination interferon alfa-2b plus ribavirin regimen
possible for the first line treatment in patients with chronic hepatitis C?
The ALGOVIRC Project Group. Hepatology 2000;31:211-218.
280. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost
effectiveness of interferon alpha2b combined with ribavirin for the
treatment of chronic hepatitis C. Hepatology 1999;30:1318-1324.
281. Zavaglia C, Airoldi A, Pinzello G. Antiviral therapy of HBV-
and HCV-induced liver cirrhosis. J Clin Gastroenterol 2000;30:234-241.
282. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances
the efficacy but not the adverse effects of interferon in chronic hepatitis
C. Meta-analysis of individual patient data from European centers. J Hepatol
1997;26:961-966.
283. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for
patients with chronic hepatitis C: Results of a placebo-controlled study. J
Hepatol 1996;25:591-598.
284. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and
efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter
trial. Hepatology 1997; 26:473-477.
285. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of
ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-654.
286. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary
trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
287. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as
initial treatment for chronic hepatitis B in the United States. N Engl J Med
1999;341:1256-1263.
288. Dienstag JL, Schiff ER, Mitchell M, et al. Extended
lamivudine retreatment for chronic hepatitis B: maintenance of viral
suppression after discontinuation of therapy. Hepatology 1999;30:1082-1087.
289. Dusheiko G. Lamivudine treatment of chronic hepatitis B. Rev
Med Virol 1998;8:153-159.
290. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence
of hepatitis B virus resistance to lamivudine in human immunodeficiency
virus-infected patients. Hepatology 1999;30:1302-1306.
291. Buti M, Jardi R, Cotrina M, et al. Transient emergence of
hepatitis B variants in a patient with chronic hepatitis B resistant to
lamivudine. J Hepatol 1998;28:510-513.
292. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of
hepatitis B viremia and emergence of YMDD variants in patients with chronic
hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762.
293. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment
serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and
graft re-infection after liver transplantation. J Hepatol 1999;30:715-721.
294. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine
resistant hepatitis B virus infection in the liver transplant recipient. Gut
2000;46:107-113.
295. Hagmeyer KO, Pan YY . Role of lamivudine in the treatment of
chronic hepatitis B virus infection. Ann Pharmacother 1999;33:1104-1112.
296. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term
follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B
treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
297. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and
alpha interferon combination treatment of patients with chronic hepatitis B
infection: a randomised trial. Gut 2000;46:562-568.
298. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine
on replication of hepatitis B virus in HIV-infected men. Ann Intern Med
1996;125:705-712.
299. Keating MR. Antiviral agents for non-human immunodeficiency
virus infections. Mayo Clin Proc 1999;74:1266-1283.
300. Angus PW. Review: hepatitis B and liver transplantation. J
Gastroenterol Hepatol 1997;12:217-223.
301. Grellier L, Dusheiko GM. Hepatitis B virus and liver
transplantation: concepts in antiviral prophylaxis. J Viral Hepat 1997;4(suppl
1):111-116.
302. Dusheiko G. Lamivudine therapy for hepatitis B infection.
Scand J Gastroenterol Suppl 1999;230:76-81.
303. Jubin R, Murray MG, Howe AY, et al. Amantadine and
rimantadine have no direct inhibitory effects against hepatitis C viral
protease, helicase, ATPase, polymerase, and internal ribosomal entry
site-mediated translation. J Infect Dis 2000;181:331-334.
304. Smith JP. Treatment of chronic hepatitis C with amantadine.
Dig Dis Sci 1997;42:1681-1687.
305. Khalili M, Denham C, Perrillo R. Interferon and ribavirin
versus interferon and amantadine in interferon nonresponders with chronic
hepatitis C. Am J Gastroenterol 2000;98:1284-1289.
306. Parolin MB, Lacerda MA, Lopes RW. [Amantadine-HCL in the
treatment of chronic hepatitis C in non-responders to alpha-interferon.
Effect on ALT serum levels and viral load]. Arq Gastroenterol 1999;36:63-67.
307. Younossi ZM, Perrillo RP. The roles of amantadine,
rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with
alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis
1999;19 (suppl 1):95-102.
308. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of
thymosin alpha1 in patients with chronic hepatitis B: a randomized,
controlled trial. Hepatology 1998; 27:1383-1387.
309. Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1
treatment of chronic hepatitis B: results of a phase III multicentre,
randomized, double-blind and placebo-controlled study. J Viral Hepat 1999;6:397-403.
310. Berger DP, Homann D, Oldstone MB. Defining parameters for
successful immunocytotherapy of persistent viral infection. Virology 2000;266:257-263.
311. Carreno V, Zeuzem S, Hopf U, et al. A phase I/II study of
recombinant human interleukin-12 in patients with chronic hepatitis B. J
Hepatol 2000;32:317-324.
312. Deniz Ayli M, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect
of oral levamisole supplementation to hepatitis B vaccination on the rate of
immune response in chronic hemodialysis patients. Nephron 2000;84:291-292.
313. Krastev Z, Jelev D, Antonov K, Alagozian V, Kotzev I. Chronic
HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or
anti-HBe positive patients--a pilot study. Hepatogastroenterology 1999;46:3184-3188.
314. Oess S, Hildt E. Novel cell permeable motif derived from the
PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 2000;7:750-758.
315. Heijtink RA, van Bergen P, Paulij WP, de Man RA, Osterhaus AD.
Anti-HBs characteristics after hepatitis B immunisation with plasma-derived
and recombinant DNA-derived vaccines. Vaccine 2000;18:1531-1538.
316. von Herrath MG, Berger DP, Homann D, et al. Vaccination to
treat persistent viral infection. Virology 2000;268:411-419.
317. McHutchison JG, Younossi Z. Treatment strategies for
hepatitis C: making the best of limited options. Cleve Clin J Med 2000;67:1-5.
318. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic
liver transplantation. Gastroenterology 1997;112:575-582.
319. Rosen HR, Chou S, Sasaki AW, Gretch DR. Molecular
epidemiology of hepatitis C infection in U.S. veteran liver transplant
recipients: evidence for decreasing relative prevalence of genotype 1B. Am J
Gastroenterol 1999;94:3015-3019.
320. al-Hemsi B, McGory RW, Shepard B, et al. Liver
transplantation for hepatitis B cirrhosis: clinical sequela of passive
immunization. Clin Transplant 1996;10:668-675.
321. Han SH, Kinkhabwala M, Martin P, et al. Resolution of
recurrent hepatitis B in two liver transplant recipients treated with
famciclovir. Am J Gastroenterol 1998;93:2245-2247.
322. Malkan G, Cattral MS, Humar A, et al. Lamivudine for
hepatitis B in liver transplantation: a single-center experience.
Transplantation 2000;69:1403-1407.
323. Sheiner PA, Boros P, Klion FM, et al. The efficacy of
prophylactic interferon alfa-2b in preventing recurrent hepatitis C after
liver transplantation. Hepatology 1998;28:831-838.
324. Singh N, Gayowski T, Wannstedt CF, Marino IR, Wagener MM.
Interferon-alpha therapy for hepatitis C virus recurrence after liver
transplantation: long-term response with maintenance therapy. Clin
Transplant 1996;10:348-351.
325. Feray C, Samuel D, Gigou M, et al. An open trial of
interferon alfa recombinant for hepatitis C after liver transplantation:
antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
326. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha
for prophylaxis of recurrent viral hepatitis C in liver transplant
recipients: a prospective, randomized, controlled trial. Transplantation
1998;65:82-86.
327. Gane EJ, Lo SK, Riordan SM, et al. A randomized study
comparing ribavirin and interferon alfa monotherapy for hepatitis C
recurrence after liver transplantation. Hepatology 1998;27:1403-1407.
328. McHutchison JG. Ribavirin and interferon for recurrent
posttransplantation HCV infection: to treat or not to treat? Hepatology
1997;26:505-506.
329. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT.
NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
330. Tong MJ, Lai LP, Murakami-Mori K. Development of
hepatocellular carcinoma after clearance of hepatitis C virus with
interferon therapy. West J Med 1997;167:103-105.
331. Effect of interferon-alpha on progression of cirrhosis to
hepatocellular carcinoma: a retrospective cohort study. International
Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535-1539.
332. Fasani P, Sangiovanni A, De Fazio C, et al. High prevalence
of multinodular hepatocellular carcinoma in patients with cirrhosis
attributable to multiple risk factors. Hepatology 1999;29:1704-1707.
333. Haydon GH, Hayes PC . Screening for hepatocellular carcinoma.
Eur J Gastroenterol Hepatol 1996;8:856-860.
334. Van Roey G, Fevery J, Van Steenbergen W. Hepatocellular
carcinoma in Belgium: clinical and virological characteristics of 154
consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol
Hepatol 2000;12:61-66.
335. Cottone M, Turri M, Caltagirone M, et al. Screening for
hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year
prospective study by ultrasound and alphafetoprotein. J Hepatol 1994;21:1029-1034.
336. Dusheiko GM, Conradie JC, Bowyer SM, et al. Small and
asymptomatic hepatocellular carcinoma detected by alpha-fetoprotein
screening in black hepatitis B carriers. A report of 2 cases. S Afr Med J
1986;69:129-132.
337. Neumayr G, Propst A, Schwaighofer H, Judmaier G, Vogel W.
Lack of evidence for the heterosexual transmission of hepatitis C. QJM 1999;92:505-508.
338. Cottone M, Turri M, Caltagirone M, et al. Early detection of
hepatocellular carcinoma associated with cirrhosis by ultrasound and
alfafetoprotein: a prospective study. Hepatogastroenterology 1988;35:101-103.
339. Curley SA, Izzo F, Gallipoli A, et al. Identification and
screening of 416 patients with chronic hepatitis at high risk to develop
hepatocellular cancer. Ann Surg 1995;222:375-380; discussion 380-383.
340. Hoofnagle JH. Serologic markers of hepatitis B virus
infection. Annu Rev Med 1981;32:1-11.
341. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion
from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann
Intern Med 1981;94:744-748.
342. Dusheiko GM. New treatments for chronic viral hepatitis B and
C. Baillieres Clin Gastroenterol 1996;10:299-333.
343. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission
of hepatitis C virus among patients attending sexually transmitted diseases
clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis
1995;171:768-775.
344. Bonino F, Oliveri F, Colombatto P, Brunetto MR. Impact of
interferon-alpha therapy on the development of hepatocellular carcinoma in
patients with liver cirrhosis: results of an international survey. J Viral
Hepat 1997;4(suppl 2):79-82.
345. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon
treatment may prevent hepatocellular carcinoma in HCV- related liver
cirrhosis. J Hepatol 1996;24:141-147.
346. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y.
Interferon alfa for patients with clinically apparent cirrhosis due to
chronic hepatitis B. Gastroenterology 1993;104:1116-1121.
347. Rakela J, Wood JR, Czaja AJ, et al. Long-term versus
short-term treatment with recombinant interferon alfa-2a in patients with
chronic hepatitis B: a prospective, randomized treatment trial. Mayo Clin
Proc 1990;65:1330-1335.
348. Leung N. Nucleoside analogues in the treatment of chronic
hepatitis B. J Gastroenterol Hepatol 2000;15:E53-E60.
349. Hoofnagle JH, Lau D . New therapies for chronic hepatitis B.
J Viral Hepat 1997;4(suppl 1):41-50.
350. Davis GL, Lindsay K, Albrecht J, et al. Clinical predictors
of response to recombinant interferon-alpha treatment in patients with
chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional
Therapy Group. J Viral Hepat 1994; 1:55-63.
351. Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a
useful predictor of response to interferon therapy in chronic hepatitis C.
Histopathology 1998;32:454-461.
352. Neuman MG, Benhamou JP, Martinot M, et al. Predictors of
sustained response to alpha interferon therapy in chronic hepatitis C. Clin
Biochem 1999;32:537-545.
353. Marcellin P, Martinot M, Erlinger S. Early negative tests for
serum HCV RNA as a predictor of sustained response to interferon therapy in
patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:237-238.
354. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus
interferon trials. Hepatology 1997;26(suppl 1):101S-107S.
355. Farci P, Mandas A, Coiana A, et al. Treatment of chronic
hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
356. Malaguarnera M, Restuccia S, Pistone G, et al. A
meta-analysis of interferon-alpha treatment of hepatitis D virus infection.
Pharmacotherapy 1996;16:609-614.
357. Di Marco V, Giacchino R, Timitilli A, et al. Long-term
interferon-alpha treatment of children with chronic hepatitis delta: a
multicentre study. J Viral Hepat 1996;3:123-128.
358. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French
experience of treatment of chronic type D hepatitis with a 12-month course
of interferon alpha-2B. Results of a randomized controlled trial. Liver
1995;15:45-52.
359. Castiglia PT. Hepatitis in children. J Pediatr Health Care
1996;10:286-288.
360. Fishman LN, Jonas MM, Lavine JE. Update on viral hepatitis in
children. Pediatr Clin North Am 1996;43:57-74.
361. Romero R, Lavine JE . Viral hepatitis in children. Semin
Liver Dis 1994;14:289-302.
362. Levinthal G, Ray M. Hepatitis A: from epidemic jaundice to a
vaccine-preventable disease. Gastroenterologist 1996;4:107-117.
363. Aristegui J, Morales JL, Dal-Re R, et al. Safety and
immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5
years old. Infection 1995;23:334-338.
364. Diaz-Mitoma F, Law B, Parsons J. A combined vaccine against
hepatitis A and B in children and adolescents. Pediatr Infect Dis J 1999;18:109-114.
365. Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety
and immunogenicity of an inactivated hepatitis A vaccine in preschool
children. J Infect Dis 1995; 171(suppl 1):S70-S72.
366. Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona
L, et al. Safety, immunogenicity and antibody persistence of an
inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 1999;18:656-664.
367. Ragni MV, Lusher JM, Koerper MA, Manco-Johnson M, Krause DS.
Safety and immunogenicity of subcutaneous hepatitis A vaccine in children
with haemophilia. Haemophilia 2000;6:98-103.
368. Ott MJ, Aruda M. Hepatitis B vaccine. J Pediatr Health Care
1999;13:211-216.
369. Corrarino JE. Perinatal hepatitis B: update &
recommendations. MCN Am J Matern Child Nurs 1998;23:246-252.
370. Golebiowska M, Kardas-Sobantka D, Chlebna-Sokol D, Sabanty W.
Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999;158:293-297.
371. Hoofnagle JH. Alpha-interferon therapy of chronic hepatitis
B. Current status and recommendations. J Hepatol 1990;11(suppl 1):S100-S107.
372. Ballauff A, Schneider T, Gerner P, et al. Safety and efficacy
of interferon retreatment in children with chronic hepatitis B. Eur J
Pediatr 1998;157:382-385.
373. Gurakan F, Kocak N, Ozen H, Yuce A. Comparison of standard
and high dosage recombinant interferon alpha 2b for treatment of children
with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-56.
374. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa
therapy for chronic hepatitis B in children: a multinational randomized
controlled trial. Gastroenterology 1998;114:988-995.
375. Jara P, Bortolotti F. Interferon-alpha treatment of chronic
hepatitis B in childhood: a consensus advice based on experience in European
children. J Pediatr Gastroenterol Nutr 1999;29:163-170.
376. Torre D, Tambini R. Interferon-alpha therapy for chronic
hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-137.
377. Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a
meta-analysis of published studies in pediatric chronic hepatitis B. Acta
Gastroenterol Belg 1998;61:219-223.
378. Ruiz-Moreno M, Leal-Orozco A, Millan A. Hepatitis C virus
infection in children. J Hepatol 1999;31(suppl 1):124-129.
379. Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus
infection and related liver disease in children of mothers with antibodies
to the virus. J Pediatr 1997;130:990-993.
380. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical
outcome of hepatitis C infection in children who underwent cardiac surgery
before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
381. Zwiener RJ, Fielman BA, Cochran C, et al. Interferon-alpha-2b
treatment of chronic hepatitis C in children with hemophilia. Pediatr Infect
Dis J 1996;15:906-908.
382. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant
interferon-alfa therapy in children with chronic hepatitis C. Hepatology
1995;22:1623-1627.
383. Jonas MM, Ott MJ, Nelson SP, Badizadegan K, Perez-Atayde AR.
Interferon-alpha treatment of chronic hepatitis C virus infection in
children. Pediatr Infect Dis J 1998;17:241-246.
384. Sawada A, Tajiri H, Kozaiwa K, et al. Favorable response to
lymphoblastoid interferon-alpha in children with chronic hepatitis C. J
Hepatol 1998;28:184-188.
385. Castro A, Buti M, Esteban R, et al. [A study of 158 cases of
acute delta hepatitis]. Med Clin (Barc) 1990;95:321-323.
386. Kleiner D, Di Bisceglie AM, Axiotis CA, Hoofnagle JH.
Prolonged alpha interferon therapy for chronic delta hepatitis: effect on
liver histopathology. Prog Clin Biol Res 1993;382:365-371.
387. Di Bisceglie AM, Martin P, Lisker-Melman M, et al. Therapy of
chronic delta hepatitis with interferon alfa-2b. J Hepatol 1990;11(suppl
1):S151-S154.
388. Hoofnagle J, Mullen K, Peters M, et al. Treatment of chronic
delta hepatitis with recombinant human alpha interferon. Prog Clin Biol Res
1987;234:291-298.
389. Hoofnagle JH, Di Bisceglie AM. Therapy of chronic delta
hepatitis: overview. Prog Clin Biol Res 1993;382:337-343.
390. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH.
Resolution of chronic delta hepatitis after 12 years of interferon alfa
therapy. Gastroenterology 1999;117:1229-1233.
391. Arora NK, Panda SK, Nanda SK, et al. Hepatitis E infection in
children: study of an outbreak. J Gastroenterol Hepatol 1999;14:572-577.
392. Smith JL. Foodborne infections during pregnancy. J Food Prot
1999;62:818-829.
393. Priddy KD. Immunologic adaptations during pregnancy. J Obstet
Gynecol Neonatal Nurs 1997;26:388-394.
394. Hunt CM, Sharara AI . Liver disease in pregnancy. Am Fam
Physician 1999;59:829-836.
395. Duff P. Hepatitis in pregnancy. Semin Perinatol 1998;22:277-283.
396. Mishra L, Seeff LB. Viral hepatitis, A though E, complicating
pregnancy. Gastroenterol Clin North Am 1992;21:873-887.
397. Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine
transmission of hepatitis A virus. Obstet Gynecol 1996;88:690-691.
398. Preventing hepatitis A infections. National Advisory Committee on
Immunization statement. Laboratory Centre for Disease Control [comment]. Can
Fam Physician 1995;41:1222-1228.
399. Supplementary statement on hepatitis A prevention. Laboratory Centre
for Disease Control. CMAJ 1996;155:302-305.
400. Goudeau A, Lo KJ, Coursaget P, et al. Prevention of hepatitis
B virus infection in children born to HBsAg positive/HBeAg positive mothers.
Preliminary results of active and passive-active immunization. Dev Biol
Stand 1983;54:399-404.
401. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A.
Long-term hepatitis B vaccine in infants born to hepatitis B e antigen
positive mothers. Arch Dis Child Fetal Neonatal Ed 1997;77:F47-F51.
402. Papaevangelou G, Hoofnagle JH. Transmission of hepatitis B
virus infection by asymptomatic chronic HBsAg carrier mothers. Pediatrics
1979;63:602-605.
403. Berger A, Doerr HW, Weber B. Human immunodeficiency virus and
hepatitis B virus infection in pregnancy: diagnostic potential of viral
genome detection. Intervirology 1998;41:201-207.
404. Roudot-Thoraval F, Pawlotsky JM, Thiers V, et al. Lack of
mother-to-infant transmission of hepatitis C virus in human immunodeficiency
virus-seronegative women: a prospective study with hepatitis C virus RNA
testing. Hepatology 1993;17:772-777.
405. Recommendations for preventing transmission of human
immunodeficiency virus and hepatitis B virus to patients during
exposure-prone invasive procedures. Centers for Disease Control. Bull Am
Coll Surg 1991;76:29-37.
406. Boxall E. Screening of pregnant women for hepatitis B.
Vaccine 1998;16(suppl):S30-S33.
407. Freitag-Koontz MJ. Prevention of hepatitis B and C
transmission during pregnancy and the first year of life. J Perinat Neonatal
Nurs 1996;10:40-55.
408. Gillett P, Hallam N, Mok J. Vertical transmission of
hepatitis C virus infection. Scand J Infect Dis 1996;28:549-552.
409. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in
injecting drug-using women during and after pregnancy. J Gastroenterol
Hepatol 2000;15:175-181.
410. Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT
and increase in serum HCV RNA during pregnancy in women with chronic
hepatitis C. J Hepatol 2000;32:293-299.
411. Wejstal R, Widell A, Norkrans G. HCV-RNA levels increase
during pregnancy in women with chronic hepatitis C. Scand J Infect Dis 1998;30:111-113.
412. Locatelli A, Roncaglia N, Arreghini A, et al. Hepatitis C
virus infection is associated with a higher incidence of cholestasis of
pregnancy. Br J Obstet Gynaecol 1999;106:498-500.
413. Hunt CM, Carson KL, Sharara AI. Hepatitis C in pregnancy.
Obstet Gynecol 1997;89:883-890.
414. Manzini P, Saracco G, Cerchier A, et al. Human
immunodeficiency virus infection as risk factor for mother-to-child
hepatitis C virus transmission; persistence of anti-hepatitis C virus in
children is associated with the mother's anti-hepatitis C virus
immunoblotting pattern. Hepatology 1995;21:328-332.
415. Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission
of hepatitis C virus. J Hepatol 1999;31(suppl 1):96-100.
416. Burns DN, Minkoff H . Hepatitis C: screening in pregnancy.
Obstet Gynecol 1999;94:1044-1048.
417. Jain A, Kar P, Madan K, et al. Hepatitis C virus infection in
sporadic fulminant viral hepatitis in North India: cause or co-factor? Eur J
Gastroenterol Hepatol 1999;11:1231-1237.
418. Madan K, Gopalkrishna V, Kar P, et al. Detection of hepatitis
C and E virus genomes in sera of patients with acute viral hepatitis and
fulminant hepatitis by their simultaneous amplification in PCR. J
Gastroenterol Hepatol 1998;13:125-130.
419. Khuroo MS, Kamili S, Jameel S. Vertical transmission of
hepatitis E virus. Lancet 1995;345:1025-1026.
420. Pereira BJ. Hepatitis C virus infection in dialysis: a
continuing problem. Artif Organs 1999;23:51-60.
421. Outbreaks of hepatitis B virus infection among hemodialysis
patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep
1996;45:285-289.
422. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National
surveillance of dialysis associated diseases in the United States, 1995.
ASAIO J 1998;44:98-107.
423. Alter MJ, Favero MS, Maynard JE. Hepatitis B vaccine use in
chronic hemodialysis centers in the United States. JAMA 1985;254:3200-3202.
424. Hutin YJ, Goldstein ST, Varma JK, et al. An outbreak of
hospital-acquired hepatitis B virus infection among patients receiving
chronic hemodialysis. Infect Control Hosp Epidemiol 1999;20:731-735.
425. Lettau LA, Alfred HJ, Glew RH, et al. Nosocomial transmission
of delta hepatitis. Ann Intern Med 1986;104:631-635.
426. Lyerla R, Kellerman S, Alter MJ. Hepatitis B and hemodialysis:
the impact of universal precautions in preventing the transmission of
bloodborne viruses. Infect Control Hosp Epidemiol 1999;20:156-157.
427. Zamir D, Storch S, Zonder HB, Zamir C, Weiner P. Hepatitis C
virus seroconversion and genotype prevalence in patients and staff on
chronic hemodialysis. J Clin Gastroenterol 1999;28:23-28.
428. Akarsu E, Zeki Tonbul H, Selcuk Y, Kaya H. Transmission of
hepatitis C virus infection to spouses of patients undergoing chronic
hemodialysis. Nephron 1999;82:359-360.
429. Galbraith RM, Eddleston AL, Portmann B, Williams R, Gower PE.
Chronic liver disease developing after outbreak of HBsAG-negative hepatitis
in haemodialysis unit. Lancet 1975;2:886-890.
430. Grethe S, Gemsa F, Monazahian M, et al. Molecular
epidemiology of an outbreak of HCV in a hemodialysis unit: direct sequencing
of HCV-HVR1 as an appropriate tool for phylogenetic analysis. J Med Virol
2000;60:152-158.
431. Irish DN, Blake C, Christophers J, et al. Identification of
hepatitis C virus seroconversion resulting from nosocomial transmission on a
haemodialysis unit: implications for infection control and laboratory
screening. J Med Virol 1999;59:135-140.
432. Kao JH, Huang CH, Chen W, et al. GB virus C infection in
hemodialysis patients: molecular evidence for nosocomial transmission. J
Infect Dis 1999;180:191-194.
433. Katsoulidou A, Paraskevis D, Kalapothaki V, et al. Molecular
epidemiology of a hepatitis C virus outbreak in a haemodialysis unit.
Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Nephrol Dial
Transplant 1999;14:1188-1194.
434. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective
analysis of the factors influencing the antibody response to hepatitis B
vaccine in hemodialysis patients. Am J Kidney Dis 1997;29:239-245.
435. Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus
infection in chronic uremia: long-term follow-up of a two-step integrated
protocol of vaccination. Am J Kidney Dis 1994;23:537-542.
436. Quiroga JA, Castillo I, Porres JC, et al. Recombinant
gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis
patients. Hepatology 1990;12:661-663.
437. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of
alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic
hemodialysis or with normal renal function: clinical implications. J Am Soc
Nephrol 1998;9:2344-2348.
438. Harnett JD, Parfrey PS, Kennedy M, et al. The long-term
outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis
1988;11:210-213.
439. Degott C, Degos F, Jungers P, et al. Relationship between
liver histopathological changes and HBsAg in 111 patients treated by
long-term hemodialysis. Liver 1983;3:377-384.
440. Lindsay KL, Redeker AG, Ashcavai M. Delayed HBsAg clearance
in chronic hepatitis B viral infection. Hepatology 1981;1:586-589.
441. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B
surface antigenemia in a chronic hemodialysis program: lack of influence on
morbidity and mortality. Am J Kidney Dis 1987;9:456-461.
442. Chauveau P. Epidemiology of hepatitis C virus infection in
chronic haemodialysis. Nephrol 1996;11(suppl 4):39-41.
443. Di Lallo D, Miceli M, Petrosillo N, Perucci CA, Moscatelli M.
Risk factors of hepatitis C virus infection in patients on hemodialysis: a
multivariate analysis based on a dialysis register in Central Italy. Eur J
Epidemiol 1999;15:11-14.
444. DuBois DB, Gretch D, dela Rosa C, et al. Quantitation of
hepatitis C viral RNA in sera of hemodialysis patients: gender-related
differences in viral load. Am J Kidney Dis 1994;24:795-801.
445. Fabrizi F, Martin P, Dixit V, et al. Detection of de novo
hepatitis C virus infection by polymerase chain reaction in hemodialysis
patients. Am J Nephrol 1999;19:383-388.
446. Rampino T, Arbustini E, Gregorini M, et al. Hemodialysis
prevents liver disease caused by hepatitis C virus: role of hepatocyte
growth factor. Kidney Int 1999;56:2286-2291.
447. Pol S, Zylberberg H, Fontaine H, Brechot C. Treatment of
chronic hepatitis C in special groups. J Hepatol 1999;31(suppl 1):205-209.
448. Izopet J, Rostaing L, Moussion F, et al. High rate of
hepatitis C virus clearance in hemodialysis patients after interferon-alpha
therapy. J Infect Dis 1997;176:1614-1617.
449. Chan PC, Lok AS, Cheng IK, Chan MK. The impact of donor and
recipient hepatitis B surface antigen status on liver disease and survival
in renal transplant recipients. Transplantation 1992;53:128-131.
450. Locasciulli A, Testa M, Valsecchi MG, et al. The role of
hepatitis C and B virus infections as risk factors for severe liver
complications following allogeneic BMT: a prospective study by the
Infectious Disease Working Party of the European Blood and Marrow
Transplantation Group. Transplantation 1999;68:1486-1491.
451. Chen PM, Chiou TJ, Fan FS, et al. Fulminant hepatitis is
significantly increased in hepatitis B carriers after allogeneic bone marrow
transplantation. Transplantation 1999;67:1425-1433.
452. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone
marrow transplantation from HBsAg+ donors: a multicenter study from the
Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995;86:3236-3240.
453. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The
clinical course of transplantation-associated de novo hepatitis B infection
in the liver transplant recipient. Liver Transpl Surg 1997;3:105-111.
454. Cavallari A, Vivarelli M, D'Errico A, et al. Fatal
necrotizing pancreatitis caused by hepatitis B virus infection in a liver
transplant recipient. J Hepatol 1995;22:685-690.
455. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini
SA. The sequential occurrence of viral mutations in a liver transplant
recipient re-infected with hepatitis B: hepatitis B immune globulin escape,
famciclovir non-response, followed by lamivudine resistance resulting in
graft loss. J Hepatol 1998;29:669-675.
456. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after
hepatitis B immune globulin is effective in preventing hepatitis B
recurrence after liver transplantation. Liver Transpl 2000;6:434-439.
457. Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic
failure in a renal transplant recipient with positive hepatitis B surface
antigens: a case report of fibrosing cholestatic hepatitis.
Hepatogastroenterology 1995;42:913-918.
458. Post AB, Hricik DE, Sterling RK, et al. Resolution of
hepatitis B viremia in a renal transplant recipient treated with alpha-2b
interferon. Nephron 1998;79:469-471.
459. Younossi ZM, Braun WE, Protiva DA, Gifford RW Jr, Straffon RA.
Chronic viral hepatitis in renal transplant recipients with allografts
functioning for more than 20 years. Transplantation 1999;67:272-275.
460. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo
hepatitis C virus infection in heart transplant recipients. Hepatology 1999;30:1293-1298.
461. Shuhart MC, Myerson D, Spurgeon CL, et al. Hepatitis C virus
(HCV) infection in bone marrow transplant patients after transfusions from
anti-HCV-positive blood donors. Bone Marrow Transplant 1996;17:601-606.
462. Liaw YF. Hepatitis viruses under immunosuppressive agents. J
Gastroenterol Hepatol 1998;13:14-20.
463. Terrault NA, Wright TL, Pereira BJ. Hepatitis C infection in
the transplant recipient. Infect Dis Clin North Am 1995;9:943-964.
464. Ichikawa Y, Kyo M, Hanafusa T, et al. A 20-year case study of
a kidney transplant recipient with chronic active hepatitis C: clinical
course and successful treatment for late acute rejection induced by
interferon therapy. Transplantation 1998;65:134-138.
465. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis
C infection and renal transplantation on survival in end-stage renal
disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int
1998;53:1374-1381.
466. Ljungman P, Andersson J, Aschan J, et al. Oral ribavirin for
prevention of severe liver disease caused by hepatitis C virus during
allogeneic bone marrow transplantation. Clin Infect Dis 1996;23:167-169.
467. Berchtold P, Seitz M. [Immunosuppression--a tightrope walk
between iatrogenic harm and therapy]. Schweiz Med Wochenschr 1996;126:1603-1609.
468. Are booster immunisations needed for lifelong hepatitis B immunity?
European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561-565.
469. Castro F, Santaella M, Torres EA, Rodriguez-Medina JR, Gonzalez-Keelan
C. Sustained response to interferon in a patient with common variable
immunodeficiency and hepatitis C. Am J Gastroenterol 1997;92:1557-1558.
470. Kroes AC, de Man RA, Niesters HG, et al. Fatal hepatitis C
virus infection in a heart transplant recipient detectable by polymerase
chain reaction only. J Hepatol 1994;21:1113-1115.
471. Christie JM, Healey CJ, Watson J, et al. Clinical outcome of
hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2
year follow up. Clin Exp Immunol 1997;110:4-8.
472. Soriano V, Bravo R, Garcia-Samaniego J, et al. Co-infection
with several HCV genotypes enhances liver damage in patients with chronic
hepatitis C. The Hepatitis/HIV Spanish Study Group [letter]. J Infect 1997;35:202-203.
473. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J,
Pedreira J. Hepatitis C and HIV infection: biological, clinical, and
therapeutic implications. J Hepatol 1999;31(suppl 1):119-123.
474. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis
progression in human immunodeficiency virus and hepatitis C virus coinfected
patients. The Multivirc Group. Hepatology 1999;30:1054-1058.
475. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E.
Prevalence, patterns, and course of past hepatitis B virus infection in
intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000;95:1316-1322.
476. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions
between HIV and hepatitis B virus in homosexual men: effects on the natural
history of infection. AIDS 1997;11:597-606.
477. Cribier B, Rey D, Uhl G, et al. Quantification of hepatitis C
virus RNA in peripheral blood mononuclear cells: a comparison between
patients chronically infected by HCV and patients coinfected by HIV. Res
Virol 1996;147:325-332.
478. Eyster ME, Alter HJ, Aledort LM, et al. Heterosexual
co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus
(HIV). Ann Intern Med 1991;115:764-768.
479. Chang MH. Mother-to-infant transmission of hepatitis C virus.
Clin Invest Med 1996;19:368-372.
480. Thomas DL, Shih JW, Alter HJ, et al. Effect of human
immunodeficiency virus on hepatitis C virus infection among injecting drug
users. J Infect Dis 1996;174:690-695.
481. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence
of hepatitis C virus genotypes and HIV infection on histological severity of
chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J
Gastroenterol 1997;92 :1130-1134.
482. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated
liver disease in a cohort of haemophilic patients. Br J Haematol 1994;87:555-561.
483. Telfer PT, Brown D, Devereux H, Lee CA, DuSheiko GM. HCV RNA
levels and HIV infection: evidence for a viral interaction in haemophilic
patients. Br J Haematol 1994;88:397-399.
484. Soriano V, Garcia-Lerma G, Bravo R, et al. Lack of
antiretroviral effect of alpha-interferon in HIV-infected patients treated
for chronic hepatitis C [letter]. J Infect 1997;35:319-320.
485. Soriano V, Bravo R, Garcia-Samaniego J, et al. A pilot study
on the efficacy of escalating dosage of alpha-interferon for chronic
hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group.
J Infect 1997;35 :225-230.
486. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon
alpha for the treatment of chronic hepatitis C in patients infected with
human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect
Dis 1996;23:585-591.
487. Frieden TR, Ozick L, McCord C, et al. Chronic liver disease
in central Harlem: the role of alcohol and viral hepatitis. Hepatology 1999;29:883-888.
488. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression
rate of fibrosis in hepatitis C virus patients with persistently normal
alanine transaminase activity. Hepatology 1998;27:868-872.
489. Regev A, Jeffers LJ . Hepatitis C and alcohol. Alcohol Clin
Exp Res 1999;23:1543-1551.
490. Makimoto K, Higuchi S. Alcohol consumption as a major risk
factor for the rise in liver cancer mortality rates in Japanese men. Int J
Epidemiol 1999;28:30-34.
491. Mori M, Hara M, Wada I, et al. Prospective study of hepatitis
B and C viral infections. Am J Epidemiol 2000;151:131-139.
492. French SW. Ethanol and hepatocellular injury. Clin Lab Med
1996;16:289-306.
493. Nalpas B, Thiers V, Pol S, et al. Hepatitis C viremia and
anti-HCV antibodies in alcoholics. J Hepatol 1992;14:381-384.
494. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol
consumption on serum hepatitis C virus RNA and histological lesions in
chronic hepatitis C. Hepatology 1998;27:1717-1722.
495. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by
polymerase chain reaction in alcoholics: false-positive ELISA results and
the influence of infection on a clinical prognostic score. Am J
Gastroenterol 1993;88:1016-1021.
496. Poynard T, Bedossa P, Opolon P. Natural history of liver
fibrosis progression in patients with chronic hepatitis C. The OBSVIRC,
METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
497. Ganne-Carrie N, Christidis C, Chastang C, et al. Liver iron
is predictive of death in alcoholic cirrhosis: a multivariate study of 229
consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a
prospective follow up study. Gut 2000;46:277-282.
498. Craxi A, Almasio P, Di Marco V, et al. Hepatitis C virus
antibodies in chronic liver diseases of different aetiology. Ital J
Gastroenterol 1991;23:244-248.
|
